Sources | Names Used |
---|---|
CTRPv2 | sirolimus:bortezomib (250:1 mol/mol) |
PharmacoGx | sirolimus:bortezomib (250:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | EPHA2 | CTRPv2 | pan-cancer | AAC | -0.16 | 5e-05 |
mRNA | CARD10 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.0001 |
mRNA | RHOG | CTRPv2 | pan-cancer | AAC | -0.16 | 5e-05 |
mRNA | MAPKAPK3 | CTRPv2 | pan-cancer | AAC | -0.16 | 3e-06 |
mRNA | KIF13A | CTRPv2 | pan-cancer | AAC | -0.16 | 5e-05 |
mRNA | FAM212A | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-05 |
mRNA | OPHN1 | CTRPv2 | pan-cancer | AAC | -0.16 | 4e-05 |
mRNA | TSPAN4 | CTRPv2 | pan-cancer | AAC | -0.15 | 7e-05 |
mRNA | FHL2 | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-05 |
mRNA | TNFRSF1A | CTRPv2 | pan-cancer | AAC | -0.15 | 2e-05 |